Novavax, Inc. (NVAX) Research

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

Market snapshot

Symbol
NVAX
Price
$9.13
Day change
-3.89%
Market cap
$1.5B
P/E ratio
-16.97x
52-week range
6.13-11.97
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$18.00

Recent news

  • Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb

    Moderna Inc. (NASDAQ:MRNA) and Novavax Inc. (NASDAQ:NVAX) shares moved higher Monday as traders piled back into vaccine names following renewed concerns over a hantavirus outbreak tied to the MV Hondius cruise ship.

  • Hantavirus cases spark surge in pharma and biotech stocks — here's why

    Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.

  • What's Going On With Novavax Stock On Friday?

    Novavax Inc. (NASDAQ:NVAX) stock is trading higher on Friday in reaction to a surge in Moderna Inc. (NASDAQ:MRNA).

Peer companies

  • CureVac N.V. (CVAC)
  • Nektar Therapeutics (NKTR)
  • Intellia Therapeutics, Inc. (NTLA)
  • ORIC Pharmaceuticals, Inc. (ORIC)
  • Precigen, Inc. (PGEN)
  • Terns Pharmaceuticals, Inc. (TERN)
  • Trevi Therapeutics, Inc. (TRVI)
  • Upstream Bio, Inc. (UPB)

Recent insider activity

  • Newton Charles W. — M-Exempt (9520 shares) on 2026-04-25
  • Newton Charles W. — M-Exempt (9520 shares) on 2026-04-25
  • Walker Robert Edward — A-Award (99500 shares) on 2026-04-14
  • Walker Robert Edward — A-Award (66000 shares) on 2026-04-14
  • Walker Robert Edward — trade (0 shares) on 2026-04-14

Open Novavax, Inc. (NVAX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.